Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.

ABSTRACT:

Objective

The Ministry of Health (MOH), Mongolia, is considering introducing 13-valent pneumococcal conjugate vaccine (PCV13) in its national immunization programme to prevent the burden of disease caused by Streptococcus pneumoniae. This study evaluates the cost-effectiveness and budget impact of introducing PCV13 compared to no PCV vaccination in Mongolia.

Methods

The incremental cost-effectiveness ratio (ICER) of introducing PCV13 compared to no PCV vaccination was assessed using an age-stratified static multiple cohort model. The risk of various clinical presentations of pneumococcal disease (meningitis, pneumonia, non-meningitis non-pneumonia invasive pneumococcal disease and acute otitis media) at all ages for thirty birth cohorts was assessed. The analysis considered

SUBMITTER: Sundaram N 

PROVIDER: S-EPMC5297341 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature